These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 33459383)
1. Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT Gründer G; Cumming P J Neurochem; 2021 Mar; 156(5):560-562. PubMed ID: 33459383 [TBL] [Abstract][Full Text] [Related]
4. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Price DL; Bonhaus DW; McFarland K Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. Stahl SM CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570 [TBL] [Abstract][Full Text] [Related]
6. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429 [TBL] [Abstract][Full Text] [Related]
7. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related]
8. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland RH J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248 [TBL] [Abstract][Full Text] [Related]
9. Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys. Banks ML Drug Alcohol Depend; 2016 Aug; 165():260-4. PubMed ID: 27242287 [TBL] [Abstract][Full Text] [Related]
10. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
11. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
13. Serotonin 6 receptor controls Alzheimer's disease and depression. Yun HM; Park KR; Kim EC; Kim S; Hong JT Oncotarget; 2015 Sep; 6(29):26716-28. PubMed ID: 26449188 [TBL] [Abstract][Full Text] [Related]
14. (11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Andersen VL; Hansen HD; Herth MM; Dyssegaard A; Knudsen GM; Kristensen JL Bioorg Med Chem Lett; 2015 Mar; 25(5):1053-6. PubMed ID: 25655720 [TBL] [Abstract][Full Text] [Related]
15. 5‑Hydroxytryptamine 2A receptor inverse agonist pimavanserin impairs maternal behavior in postpartum female rats. Gan L; Sun M; Chen W Pharmacol Biochem Behav; 2018 Dec; 175():152-159. PubMed ID: 30393120 [TBL] [Abstract][Full Text] [Related]
17. Chronic treatments with a 5-HT Baranger K; Giannoni P; Girard SD; Girot S; Gaven F; Stephan D; Migliorati M; Khrestchatisky M; Bockaert J; Marchetti-Gauthier E; Rivera S; Claeysen S; Roman FS Neuropharmacology; 2017 Nov; 126():128-141. PubMed ID: 28844596 [TBL] [Abstract][Full Text] [Related]
18. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard C; Youakim JM; Coate B; Stankovic S J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083 [TBL] [Abstract][Full Text] [Related]
19. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Drp1 Ameliorates Synaptic Depression, Aβ Deposition, and Cognitive Impairment in an Alzheimer's Disease Model. Baek SH; Park SJ; Jeong JI; Kim SH; Han J; Kyung JW; Baik SH; Choi Y; Choi BY; Park JS; Bahn G; Shin JH; Jo DS; Lee JY; Jang CG; Arumugam TV; Kim J; Han JW; Koh JY; Cho DH; Jo DG J Neurosci; 2017 May; 37(20):5099-5110. PubMed ID: 28432138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]